Description

Difelikefalin (CR-845; FE-202845) is a peripherally restricted and selective agonist of kappa opioid receptor (KOR). Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Neuroscience-Neuromodulation–C36H53N7O6—-[1]Steven Fishbane, et al. Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients. Kidney Int Rep. 2020 Jan 28;5(5):600-610.|[2]Steven Fishbane, et al. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients With Pruritus. N Engl J Med. 2020 Jan 16;382(3):222-232.–1024828-77-0–679.85–99.50–O=C(C1(N)CCN(C([C@@H](CCCCN)NC([C@@H](CC(C)C)NC([C@@H](CC2=CC=CC=C2)NC([C@@H](CC3=CC=CC=C3)N)=O)=O)=O)=O)CC1)O–Neurological Disease–DMSO : 100 mg/mL (ultrasonic)|H2O : ≥ 100 mg/mL–Opioid Receptor–κ Opioid Receptor/KOR–GPCR/G Protein;Neuronal Signaling–Peptides